參考文獻/References:
[1] Lindsey B A, Markel J E, Kleinerman E S.Osteosarcoma Overview[J].Rheumatol Ther, 2017, 4(1):25-43.
[2] Chen Z, Wu H, Wang G H, et al.Identification of potential candidate genes for hypertensive nephropathy based on gene expression profile[J].Bmc Nephrology, 2016, 17(1):149.
[3] Gandhi M, Smith B A, Bovellan M, et al.GMF is a cofilin homolog that binds Arp2/3 complex to stimulate filament debranching and Inhibit actin nucleation[J].Curr Biol, 2010, 20(9):861-867.
[4] Lippert D N.Glia maturation factor gamma regulates the migration and adherence of human T lymphocytes[J].Bmc Immunology, 2012, 13(10):21.
[5] Aerbajinai W, Liu L, Chin K, et al.Glia maturation factor-γ mediates neutrophil chemotaxis[J].Journal of Leukocyte Biology, 2011, 90(3):529-538.
[6] Takeshi O, Yuki K, Yuichi A, et al.COXPRESdb v7: a gene coexpression database for 11 animal species supported by 23 coexpression platforms for technical evaluation and evolutionary inference[J].Nucleic Acids Research, 2019, 47(D1):D55-D62.
[7] Mahlam?ki E H, Kauraniemi P, Monni O, et al.High-resolution genomic and expression profiling reveals 105 putative amplification target genes in pancreatic cancer[J].Neoplasia, 2004, 6(5):432-439.
[8] Riina K, Kimmo S, Azorsa D O, et al.Intersex-like(IXL)is a cell survival regulator in pancreatic cancer with 19q13 amplification[J].Cancer Research, 2007, 67(5):1943-1949.
[9] Li Y L, Ye F, Cheng X D, et al.Identification of glia maturation factor beta as an independent prognostic predictor for serous ovarian cancer[J].European Journal of Cancer, 2010, 46(11):2104-2118.
[10] Wang H, Chen Z, Chang H, et al.Expression of glia maturation factor γ is associated with colorectal cancer metastasis and its downregulation suppresses colorectal cancer cell migration and invasion in vitro[J].Oncolog y Reports, 2017, 37(2):929-936.
[11] Szczerba B M, Castro-Giner F, Vetter M, et al.Neutrophils escort circulating tumour cells to enable cell cycle progression[J].Nature, 2019, 566(7745):553-557.
相似文獻/References:
[1]肖莉莉 劉 暉 賈春鋒.基于核酸適配體的微流控芯片的構建及對循環(huán)腫瘤細胞篩選性能的測定[J].福建醫(yī)藥雜志,2020,42(02):119.
[2]陳康堯,顧恩毅,蔡碰德,等.H1受體拮抗劑異丙嗪對順鉑治療骨肉瘤的影響及機制[J].福建醫(yī)藥雜志,2021,43(04):132.
CHEN Kangyao,GU Enyi,CAI Pengde,et al.Efficacy and mechanism of H1 receptor antagonist promethazine on osteosarcoma treated with cisplatin[J].FUJIAN MEDICAL JOURNAL,2021,43(02):132.
[3]鐘志輝,林焱斌,莊 研,等.骨肉瘤組織ACTN4和CD133的表達及其影響因素[J].福建醫(yī)藥雜志,2021,43(05):117.
ZHONG Zhihui,LIN Yanbin,ZHUANG Yan,et al.Expression and interfering factors of ACTN4 and CD133 in osteosarcoma[J].FUJIAN MEDICAL JOURNAL,2021,43(02):117.
[4]林東澤.shRNA沉默c-myc基因對MG-63骨肉瘤細胞c-myc/PD-L1軸的影響[J].福建醫(yī)藥雜志,2022,44(05):133.
[5]周子杰,張家豪,姜吉霖,等.miR-586通過SFRP1調控骨肉瘤細胞增殖、遷移、侵襲的機制研究[J].福建醫(yī)藥雜志,2024,46(01):115.[doi:10.20148/j.fmj.2024.01.032]